US rheumatologists continue to increase use of biologics for RA treatment The Pharma Letter These products include Bristol-Myers Squibb's Orencia SC (abatacept), and Genentech/Roche's Rituxan (rituximab) and Actemra (tocilizumab). The share increase for these three products will most likely be at the expense of Amgen/Pfizer's Enbrel ... |
